SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Article References

DINI, Catia; FABBRI, Alessia  and  GERACI, Andrea. The potential role of garlic (Allium sativum) against the multi-drug resistant tuberculosis pandemic: a review. Ann. Ist. Super. Sanità [online]. 2011, vol.47, n.4, pp.465-473. ISSN 0021-2571.

    1. World Health Organization (WHO). Tuberculosis fact sheet. Geneva: WHO; 2010. [ Links ]

    2. World Health Organization. Tuberculosis: A global emergency. Geneva: WHO; 1994. [ Links ]

    3. World Health Organization. "Epidemiology". Global tuberculosis control: epidemiology, strategy, financing. Geneva: WHO; 2009. p. 6-33. [ Links ]

    4. World Health Organization. Global tuberculosis control 2010. Geneva: WHO; 2011. [ Links ]

    5. World Health Organization. TB/HIV A Clinical Manual, 2. ed. Geneva: WHO; 2004. [ Links ]

    6. Small PM, Shafer RW, Hopewell PC Singh SP, Murphy MG, Desmond E, Sierra MF, Schoolnik GK. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993;328:1137-44. [ Links ]

    7. World Health Organization. Multidrug and extensively drugresistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: WHO; 2011. [ Links ]

    8. World Health Organization. Global tuberculosis control: short update to 2009 report. Geneva: WHO; 2009. [ Links ]

    9. Zhao M, Li X, Xu P, Shen X, Gui X, Wang L, DeRiemer K, Mei J, Gao Q. Transmission of MDR and XDR Tuberculosis in Shanghai, China. Plos One 2009;4(2):e4370. [ Links ]

    10. Victor TC, Streicher EM, Kewley C, Jordaan AM, van der Spuy GD, Bosman M, Louw H, Murray M, Young D, van Helden PD, Warren RM. Spread of an emerging Mycobacterium tuberculosis drug-resistant strain in the Western Cape of South Africa. Int J Tuberc Lung Dis 2007;11(2):195-201. [ Links ]

    11. Suchindran S, Brouwer ES, Van Rie A. Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review Plos One 2009;4(5):e5561. [ Links ]

    12. Stuckler D, Basu S, McKee M. Governance of Mining, HIV and Tuberculosis in Southern Africa. Global Health Governance fall 2010;4(1). [ Links ]

    13. Rees D, Murray J, Nelson G, Sonnenberg P. Oscillating migration and the epidemics of Silicosis, tuberculosis, and HIV infection in South African gold miners. Am J Ind Med 2009. [ Links ]

    14. Stuckler D, Basu S, McKee M, Lurie M. Mining and risk of tuberculosis in Sub-Saharan Africa. Am J Public Health 2011;101(3):524-30. [ Links ]

    15. National Institute for Occupational Health (NIOH). Pathology division, surveillance Report: demographic data and disease rates for January to December 2009. Johannesburg: NIOH; 2010. [ Links ]

    16. Corbett EL, Churchyard GJ, Clayton TC, Williams BG, Mulder D, Hayes RJ, De Cock KM. HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners. AIDS 2000;14(17):2759-68. [ Links ]

    17. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfray-Faussett P, Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort Study in South African gold miners. J Infect Dis 2005;191:150. [ Links ]

    18. Glynn JR, Murray J, Bester A, Nelson G, Shearer S, Sonnenberg P. Effects of duration of HIV infection and secondary tuberculosis transmission on tuberculosis incidence in the South African gold mines. AIDS 2008;22(14):1859-67. [ Links ]

    19. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients coinfected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368(9547):1575-80. [ Links ]

    20. Singh JA, Upshur R, Padayatchi N. XDR-TB in South Africa: No time for denial or complacency. Plos Med 2007;4(1): e50:19-25. [ Links ]

    21. Ködmön C, Hollo V, Huitric E, Amato-Gauci A, Manissero D. Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union and European Economic Area 4. Euro Surveill 2010;15(11):4-8. [ Links ]

    22. European Centre for Disease Prevention and Control (ECDC) and WHO. Europe Tuberculosis surveillance in Europe 2009. ECDC-WHO: 2011. [ Links ]

    23. European Centre for Disease Prevention and Control (ECDC) and WHO. Europe Tuberculosis surveillance in Europe 2008. ECDC-WHO: 2010. [ Links ]

    24. Lefebvre N, Falzon D.Risk factors for death among tuberculosis cases: analysis of European surveillance data. Eur Respir J 2008;31:1256-60. [ Links ]

    25. Paganelli M. Diagnosi troppo in ritardo ed è allarme multi resistenza. La Repubblica 22 March 2011. [ Links ]

    26. Istituto Superiore di Sanità (ISS), Ministero della Salute (MS), Agenzia Sanitaria e Sociale Regione Emilia-Romagna (ASS-RER). Rapporto: La Tubercolosi in Italia Anno 2008. Roma: ISS-MS-ASS-RER; 2010. [ Links ]

    27. Besozzi G. Tubercolosi in Italia: 5000 casi ufficiali, ma sottostimati. 11 March 2011. [ Links ]

    28. World Health Organization. Tuberculosis (TB) Pursue highquality DOTS expansion and enhancement. Geneva: WHO; 2011. [ Links ]

    29. Nathanson E, Lambregts-van Weezenbeek C, Rich ML, Gupta R, Bayona J, Blöndal K, Caminero JA, Cegielski JP, Danilovits M, Espinal MA, Hollo V, Jaramillo E, Leimane V, Mitnick CD, Mukherjee JS, Nunn P; Pasechnikov A, Tupasi T, Wells C, Raviglione MC. Multidrug-resistant Tuberculosis management in resource-limited settings. Emerg Infect Dis 2006;12(9):1389-97. [ Links ]

    30. Keshavjee S, Seung K. Stemming the tide of multi-drug resistant tuberculosis: major barriers to addressing the growing epidemic. Harvard Medical School, Partners in Health, Francois-Xavier Bagnoud Center for Health and Human Rights, Brigham and Women's Hospital; 2008. [ Links ]

    31. Pozniak AL, Miller RL, Ormerod P. The treatment of tuberculosis in HIV-infected persons. AIDS 1999;13:435-45. [ Links ]

    32. Yenny. Pharmacokinetic interactions between rifampicin and efavirenz in HIV-TB coinfections. Univ Med 2009;28(3):188-201. [ Links ]

    33. Deana GL, Edwardsb SG, Ivesb NJ, Matthewsc G, Foxd EF, Navaratnea L, Fishere M, Taylorf GP, Millerg R, Taylorb CB, de Ruitera A, Pozniakc AL. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002;16(1). [ Links ]

    34. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, ZiaZarifi A, H.and Hoffner SE. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally 35. drug-resistant strains in Iran. Chest 2009;136:420-5. [ Links ]

    35. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, Jensen P, Bayona J. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010;375:1830-43. [ Links ]

    36. Du Cros P. MSF: The problem of multidrug resistant TB (MDR-TB). Médecins sans frontières (MSF): 2010. [ Links ]

    37. Tupasi TE, Gupta R, Imelda M, Quelapio D, Orillaza RB, Mira NR, Mangubat NV, Belen V, Arnisto N, Macalintal L, Arabit M, Lagahid JY, Espinal M, Floyd K. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med 2006;3(9): e352:1587-96. [ Links ]

    38. World Health Organization. The feasibility and efficiency of controlling MDR-TB using the DOTS-Plus strategy in the Russian Federation, Policy Brief N. 3. Geneva: WHO; 2005. [ Links ]

    39. Médecins sans frontières (MSF). Tubercolosi: I nuovi volti di una vecchia malattia. MSF: 2009. [ Links ]

    40. World Health Organization. Tuberculosis, financing M/XDRTB control and care. Geneva: WHO; 2009. [ Links ]

    41. Nathanson E, Nunn P, Uplekar M, Floyd K, Jaramillo E, Lönnroth K, Weil D, Raviglione M. MDR Tuberculosis. Critical steps for prevention and control. N Engl J Med 2010;363:1050-8. [ Links ]

    42. Donald PR, Van Helden PD. The Global Burden of Tuberculosis. Combating drug resistance in difficult times. N Engl J Med 2009;360:2393-5. [ Links ]

    43. Xu K, Evans DB, Kawabata K, Zeramdini R, Klavus J, Murray CJL. Household catastrophic health expenditure: a multicountry analysis. Lancet 2003;362:111-7. [ Links ]

    44. Keusgen M, Fritch RM, Hisoriev H, Kubornova PA, Khassanov FO. Wild Allium species (Alliaceae) used in folk medicine in Tajikistan and Uzbekistan. J Ethnob Ethnom 2006;2:18. [ Links ]

    45. Rivlin RS. Historical perspective on the use of garlic. J Nutr 2001;(131)95:951S-4S. [ Links ]

    46. Williamson EM. Major herbs of ayurveda. Dabur Research Foundation, Dabur Ayurvet Limited: Elsevier Health Sciences; 2002. p. 30-9. [ Links ]

    47. Ankri S, Mirelman D. Antimicrobial properties of Allicin from garlic. Microbes Infect 1999;1(2):125-9. [ Links ]

    48. Koch HP, Lawson LD. Garlic. The science and therapeutic application of Allium sativum L and related species. Baltimore: Williams & Wilkins; 1996 2nd ed. [ Links ]

    49. Thomson M, Ali M. Garlic (Allium sativum): a review of its potential use as an anti-cancer agent. Curr cancer drug targets 2003;3(1):67-81. [ Links ]

    50. Seki T, Hosono T, Hosono-Fukao T, Inada K, Tanaka R, Ogihara J, Ariga T. Anticancer effects of diallyl trisulfide derived from garlic. Asia Pac J Clin Nutr 2008;17(S1):249-52. [ Links ]

    51. Bat-Chen W, Golan T, Peri I, Ludmer Z, Schwarz B. Allicin purified from fresh garlic cloves induces apoptosis in colon cancer cells via Nrf2. Nutr Cancer 2010;62(7):947-57. [ Links ]

    52. Ejaz S, Woong LC, Ejaz A. Extract of garlic (Allium sativum) in cancer chemoprevention experimental. Oncology 2003;25:93-7. [ Links ]

    53. Kasuga S, Uda N, Kyo E, Ushijima M, Morihara N, Itakura Y. Pharmacological activities of aged garlic extract in comparison with other garlic preparations. J Nutr 2001;13:1080S-4S. [ Links ]

    54. Arditti FD, Rabinkov A, Miron T, Reisner Y, Berrebi A, Wilchek M, Mirelman D. Apoptotic killing of B-chronic lymphocytic leukemia tumor cells by allicin generated in situ using a rituximab-alliinase conjugate. Mol Cancer Ther 2005;4(2)325-31. [ Links ]

    55. World Health Organization "Allii Sativi Bulbus". WHO monographs on selected medicinal plants. Geneva: WHO; 1999. Vol. 1. p. 5-15. [ Links ]

    56. Lemar KM, Passa O, Aon MA, Cortassa S, Müller CT, Plummer S, O'Rourke B, Lloyd D. Allyl alcohol and garlic (Allium sativum) extract produce oxidative stress in Candida albicans. Microbiology 2005;151:3257-65. [ Links ]

    57. Bergner P. Allium sativum: antibiotic and immune properties. Medherb 1995. [ Links ]

    58. Abdullah TH. In vitro efficacy of a compound derived from garlic against pneumocystis carinii. J Natl Med Assoc 1996;88(11):694-704. [ Links ]

    59. Cutler RR, Wilson P. Antibacterial activity of a new, stable, aqueous extract of allicin against methicillin-resistant Staphylococcus aureus. Br J Biomed Sci 2004;61(2). [ Links ]

    60. Iberl B,Winkler G, Müller B, Knobloch K. Quantitative determination of Allicin and Alliin from garlic by HPLC. Planta Med 1990;56(3):320-6. [ Links ]

    61. Wills ED. Enzyme Inhibition by Allicin, the active principle of garlic. Biochem J 1956;63(3):514-20. [ Links ]

    62. Ankri S, Mirelman D. Antimicrobial properties of Allicin from garlic. Microbes Infect 1999;1(2):125-9. [ Links ]

    63. Amin M, Segatoleslami S, Hashemzadeh M. Antimycobacterial activity of partial purified extract of Allium ascalonicum. Jundishapur J Microbiol 2009;2(4):144-7. [ Links ]

    64. Bain J, Latimer HA. Garlic in whooping cough. Br Med J 1916. p. 93 quotes Dr. Minchin WC Allyl Sulphide in the treatment of Lupus and tuberculosis (1912). [ Links ]

    65. Block E. Garlic and other Alliums: the lore and the science. Cambridge: Royal Soc Chem; 2010. [ Links ]

    66. Minchin WC. A study in tubercle virus, polymorphism, and the treatment of tuberculosis and Lupus with Oleum Allii. J Am Med Assoc 1928;90(10):796. [ Links ]

    67. Minchin WC. Baillière. A study in tubercle virus, reviews of new books. Supplement to the Br Med J 1912;231. [ Links ]

    68. Bakhru HK. Foods that heal. 1990; p. 115 quotes Mc Duffie. [ Links ]

    69. Cavallito CJ, Bailey JH. Allicin, the antibacterial principle of Allium sativum. I isolation, physical properties and antibacterial action. J Am Chem Soc 1944;66(11):1950-1. [ Links ]

    70. Rao RR, Rao SS, Natarajan S, Venkataraman PR. Inhibition of Mycobacterium tuberculosis by garlic extract. Nature 1946;157. [ Links ]

    71. Delaha EC, Garagusi VF. Inhibition of mycobacteria by garlic extract Allium sativum. Antimicrob Agents Chemother 1985;27(4):485-6. [ Links ]

    72. Jain RC. Antitubercular activity of garlic oil. Indian Drugs 1993;30:73-5. [ Links ]

    73. Jain RC. Anti tubercular activity of garlic oil. Indian J Pathol and Microbiol 1998;41(1):131. [ Links ]

    74. Ratnakar P, Murthy S. Purification and mechanism of antitubercular principle from garlic (Allium sativum) active against isoniazid susceptible and resistant Mycobacterium tuberculosis H37Rv. Indian J Clin Biochem 1995;10(1):34-8. [ Links ]

    75. Ratnakar P, Murthy S. Preliminary studies on the antitubercular activity and the mechanism of action of the water extract of garlic (Allium sativum) and its two partially purified proteins (garlic defensis?). Indian J Clin Biochem 1996;11(1):37-41. [ Links ]

    76. Murthy PS, Ratnakar P, Gadre DV, Gadre V, Talwar V, Gupta HC, Gupta RL. Triofluoperazine and CEF-Allicin from garlic (Allium sativum) as potential new antitubercular drugs active against drug resistant Mycobacterium tuberculosis. Indian J Clin Biochem 1997;12(Suppl.):72-5. [ Links ]

    77. Hasan N, Yusufb N, Toossi Z, Islam N. Suppression of Mycobacterium tuberculosis induced reactive oxygen species (ROS) and TNF-a mRNA expression in human monocytes by allicin. FEBS Letters 2006;580:2517-22. [ Links ]

    78. Hasan N, Siddiqui MU, Toossi Z, Khan S, Iqbal J, Islam N. Allicin-induced suppression of Mycobacterium tuberculosis 85B mRNA in human monocytes. Biochem Biophys Res Comm 2007;355:471-6. [ Links ]

    79. Dibua UE, Odo GE, Udengwu S, Esimone CO. Cytotoxicity and antitubercular activity of Allium sativum and lantana camara against mycobacterial isolates from people living with HIV/AIDS. The Internet Journal of Infectious Diseases 2010;8(1). [ Links ]

    80. Josling P. Allicin, The heart of garlic, Nature's aid to heal the human body. Chicago: HRC Publishing; 2005. p. 137-9. [ Links ]

    81. Gupta R, Thakur B, Singh P, Singh HH, Sharma VD, Katoch VM, Chauhan SVS. Anti-tuberculosis activity of selected medicinal plants against multi-drug resistant Mycobacterium tuberculosis isolates. Indian J Med Res Jun 2010;131:809-913. [ Links ]

    82. Hannan A, Ullah MI, Usman M, Hussain S, Absar M, Javed K. Anti-mycobacterial activity of garlic (Allium sativum) against multi-drug resistant and non-multi-drug resistant Mycobacterium tuberculosis. Pak J Pharm Sci 2011;24(1):81-5. [ Links ]

    83. Gupta RL, Jain S, Talwar V, Gupta HC, Murthy PS. Antitubercular activity of garlic (Allium sativum) extract on combination with conventional antitubercular drugs in tubercular lymphadenitis. Indian J Clin Biochem 1999;14(1):12-8. [ Links ]

    84. Dhamija P, Sethi S, Meharwal S, Kumar S, Malhotra S, Sharma M, Pandhi P. Crude aqueous extract of garlic reduces MIC of isoniazid and rifampicin against Mycobacterium tuberculosis by broth microdilution method. J Compl Integr Med 2010;7(1):Article 47. [ Links ]

    85. World Health Organization, WHO traditional medicine strategy 2002-2005. Geneva: WHO; 2002. [ Links ]

    86. Newton SM, Wright CW. A review of antimycobacterial natural products. Phytother Res 2000;14(5):303-22. [ Links ]

    87. Peltzer K, Mngqundaniso N. Patients. Consulting traditional health practioners in the context of HIV/AIDS in urban areas in Kwazulu-Natal, South Africa. Afr J Tradit Complement Altern Med 2008;5(4):370-9. [ Links ]

    88. Willkinson D, Gcabashe L, Lurie M. Traditional healers as tuberculosis treatment supervisors: precedent and potential. Int J Tuberc Lung Dis 1999;3(9):838-42. [ Links ]

    89. Colvin M, Gumede L, Grimwadw K, Maher D, Willkinson D. Contribution of traditiona healers to a rural tuberculosis control programme in Hlabisa, South Africa. Int J Tuberc Lung Dis 2003;7(9 Suppl. 1):86-91. [ Links ]

    90. Brouwer JA, Boeree MJ, Kager P, Varkevisser CM, Harries AD. Traditional healers and pulmonary tuberculosis in Malawi. Int J Tuberc Lung Dis 1998;2(3):231-4. [ Links ]

    91. UNAIDS. Collaboration with traditional healers in HIV/ AIDS prevention and care in sub-Saharan Africa. A literature review. Geneva: UNAIDS; 2000. [ Links ]

    92. UNAIDS. Ancient remedies, new disease: involving traditional healers in increasing access to AIDS care and prevention in East Africa. Geneva: UNAIDS; 2002. [ Links ]

    93. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, Castro KG, Weyer K. HIV infection and multidrug-resistant tuberculosis. The perfect storm. J Infect Dis 2007;15(196 Suppl. 1):S86-107. [ Links ]

    94. Raviglione M. Tuberculosis is a global health issue: challenges and need for new tools. BMC Proceedings 2010;4(Suppl. 3):01. [ Links ]